Cubic Digital Intelligence Unveils Industry-Leading Vector Tile Delivery for TAK Users
SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 24, 2025 / Cubic Digital Intelligence (CDI), a leader in geospatial intelligence (GEOINT) and advanced full-motion video (FMV) solutions, announces the launch of its vector tile delivery system for the Tactical Assault Kit (TAK) ecosystem.
CDI's new platform, delivered through the TAKTICS dissemination system, streamlines access to vector tiles from multiple vendors, while providing direct access to mission-critical data. The capability ensures rapid, seamless and scalable geospatial data dissemination for TAK users worldwide, allowing them to quickly locate, retrieve and download the information they need with unparalleled speed and efficiency.
'Our capability represents a major leap forward in delivering next-generation geospatial intelligence to TAK users,' said Paul Sartorius, VP & General Manager at Cubic Digital Intelligence. 'We deliver fast, accurate and interactive data visualization, from sensor-to-shooter, enabling warfighters and intelligence professionals to make decisions anywhere, anytime.'
Key Benefits:
Seamless TAK Integration - Built for interoperability, the platform delivers instant access to vector tiles without time-intensive conversions or raster-based overlays.
Optimized for Performance - Unlike traditional hybrid tile approaches, the client-side rendered vectors reduce processing loads while delivering high-fidelity, interactive maps in both 2D and 3D TAK clients.
Scalable and Future-Proof - Supporting multi-vendor data sources, the platform ensures users always have access to the most up-to-date and relevant geospatial information, with no need for reprocessing or additional hardware investments.
Advancing Mission-Critical Geospatial Solutions
Vector tile solutions further enhance our commitment to delivering superior GEOINT dissemination tools that empower defense and intelligence operators with real-time, high-performance geospatial data. By eliminating the inefficiencies of burnt-in rasterization, CDI ensures TAK users can access, interact with and manipulate geospatial intelligence with unprecedented flexibility and clarity.
To learn more: Cubic Digital Intelligence.
About Cubic
Cubic delivers technology solutions in transportation that make people's lives easier by simplifying daily journeys and defense capabilities that promote mission success and safety for those who serve their nation. Led by our talented teams around the world, Cubic is driven to solve global challenges through innovation and service to customers and partners.
Part of Cubic's portfolio of businesses, Cubic Defense provides networked Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance and Reconnaissance (C5ISR) solutions and is a leading provider of live, virtual, constructive and game-based training solutions for both U.S. and Allied Forces. Mission-inspired capabilities enable assured multi-domain access; converged digital intelligence; and superior readiness for defense, intelligence, security and commercial missions. For more information, visit: Cubic Defense.
About Cubic Digital Intelligence
Cubic Digital Intelligence, a division of Cubic Corporation, is a leading provider of advanced software technologies for defense and intelligence operations. With decades of expertise in geospatial data dissemination, video management and mission-critical systems, CDI empowers organizations to make informed decisions when it matters most. We deliver decision-quality insights. Anywhere. Anytime. Visit Cubic Digital Intelligence
Media Contacts:
Geri MacDonald
Cubic Defense
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 days ago
- Business Wire
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech"), noted that its Founded Entity, Vedanta Biosciences, ('Vedanta') a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that its candidate VE202 did not meet the primary endpoint in the Phase 2 COLLECTiVE202 study for the treatment of patients with mild-to-moderate ulcerative colitis (UC). Vedanta remains focused on advancing its lead program, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI). Ulcerative colitis and CDI are distinct diseases with different underlying biology, and VE202 and VE303 have different bacterial compositions and mechanisms of action. VE303 has demonstrated positive Phase 2 results, reducing CDI recurrence risk by more than 30% compared with placebo, and is currently being evaluated in the global, registrational Phase 3 RESTORATiVE303 study. The program has received both Fast Track and Orphan Drug designations from the FDA and, if approved, is positioned to become the first live biotherapeutic product for any indication. Vedanta is also advancing VE707, designed to prevent infections caused by multidrug-resistant organisms, with an IND submission planned for 2026. Over the course of 2025, PureTech's ownership stake in Vedanta has been diluted to 4.2% on a fully diluted basis. The full text of the announcement from Vedanta is as follows: Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint VE202 was well tolerated, with no reports of treatment-related serious adverse events Additional analyses from COLLECTiVE202 to be shared in upcoming scientific forums Vedanta to focus resources on ongoing Phase 3 RESTORATiVE303 registrational study of VE303 in recurrent Clostridioides difficile infection – Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that its candidate VE202 did not meet the primary endpoint of endoscopic response in the Phase 2 COLLECTiVE202 study for the treatment of patients with mild-to-moderate ulcerative colitis (UC). 'We are very disappointed that our study did not meet its efficacy endpoints, and our greatest regret is that people living with inflammatory bowel disease will not, for now, have the opportunity to benefit from a new treatment option,' said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences. 'The gut microbiome is a well-recognized driver of IBD, yet remains a facet of the disease untouched by current treatments. As a field, we have not yet succeeded in making a meaningful impact for people with IBD through microbiome-based approaches, but every study moves us closer to that goal. We are committed to sharing further analyses of this study at upcoming scientific meetings to help chart new paths forward. 'Our priority at Vedanta remains the successful execution of our ongoing global pivotal study of VE303 for the prevention of recurrent C. difficile infection, with the goal of potentially delivering the first approved Live Biotherapeutic Product in any indication — and, in doing so, addressing a serious health condition with a significant unmet medical need,' concluded Dr. Olle. In the randomized, placebo-controlled COLLECTiVE202 study, endoscopic and clinical responses were assessed using standardized criteria, and the observed response rates in the VE202 group were not statistically different from those in the placebo group. VE202 was generally safe and well tolerated — most adverse events were mild or moderate in intensity, with no reports of treatment-related serious adverse events. Analyses of bacterial colonization, histological findings, and immune responses are ongoing and will be shared in future scientific forums. Vedanta remains focused on advancing its other pipeline programs: VE303: Vedanta is currently enrolling patients into RESTORATiVE303, a registrational Phase 3 study of VE303 for the prevention of recurrent C. difficile infection (rCDI) at over 200 sites in 24 countries. The Phase 3 program is supported by results from a positive Phase 2 study, in which VE303 demonstrated potentially best-in-disease efficacy with a 30.5% absolute risk reduction compared with placebo and greater than 80% reduction in the odds of a CDI recurrence. VE707: Vedanta is also advancing VE707 to prevent infections by multidrug-resistant organisms that affect a wide range of vulnerable populations in areas such as oncology, urology, transplantation, and critical care, with IND submission planned for 1H 2026. About the COLLECTiVE202 Study COLLECTiVE202 is a double-blind, placebo-controlled, randomized clinical trial conducted at sites in the United States, Europe, and Australia. The study enrolled 114 patients, between the ages of 18 and 75 years, with mild-to-moderate ulcerative colitis who had not been exposed to any biologic or advanced oral therapies. Either VE202 (N=57) or placebo (N=57) was added to a patient's stable background ulcerative colitis therapy. The primary endpoints were safety and Week 8 endoscopic response (defined as a reduction of at least 1 point on the Mayo endoscopic subscore). Secondary endpoints included clinical response and remission, endoscopic improvement and remission, as well as histological assessments and measures of colonization, quality-of-life and inflammatory biomarkers. For more information on COLLECTiVE202 (NCT05370885), visit About Vedanta Biosciences Vedanta Biosciences is a clinical-stage biopharmaceutical company developing microbiome-based oral medicines for the treatment of gastrointestinal diseases. The company's lead asset is a potential first-in-class therapy, VE303, currently in a global Phase 3 registrational trial for prevention of recurrent C. difficile infection. Vedanta leverages its proprietary industry-leading product engine to develop therapeutic drug candidates based on defined bacterial consortia. The product engine is supported by broad foundational intellectual property and spans the development lifecycle from discovery to commercialization. It includes one of the largest libraries of bacteria isolated from the human microbiome, vast clinical datasets, proprietary capabilities in consortium design, and end-to-end CGMP manufacturing capabilities at commercial launch scale. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to Vedanta's development plans, the applicability of the platform, potential benefits to patients, and Vedanta's and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Miami Herald
5 days ago
- Miami Herald
Cubic, ShootHouse and Digimation to Provide a Family of System Integrated Products to the Middle East and Singapore
Delivering cost-effective simulation training solutions to improve proficiency and critical decision-making skills SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Cubic Defense is proud to announce a strategic collaboration with ShootHouse and Digimation. The alliance will provide Cubic exclusivity for VIPER and DART MAX™ to customers in the Middle East and Singapore. Cubic will also provide tailor-made, in-country, operations and maintenance support to meet customer requirements. "This collaboration reflects a shared commitment to equipping global law enforcement and military teams with the most advanced and effective training solutions," said Alicia Combs, Vice President and General Manager at Cubic Defense. "The EST4000 capability delivers a tailor-made, cost-effective way to experience and learn from life-threatening situations in a safe environment to improve firearm proficiency and critical decision-making skills." EST4000 Standard (S): Based on ShootHouse's VIPER software and integrated with best-in-class add-ons depending on the customer's requirement (such as, tetherless recoil systems, shootback simulation, live fire options and weapon handling data capture). EST4000 Live, Virtual and Constructive (LVC): Built on ShootHouse's VIPER software and integrated to include a wide range of add-ons as set out for EST4000 (S). The system includes Cubic's LVC training technology, providing exposure to a wide range of proficiencies, to deliver ultimate realism, including capabilities not previously available to simulation shooting ranges (including UAV, indirect weapon effects, electronic warfare, ISTAR, helicopters, and CCTV systems). EST4000 Advanced (A): Created on Digimation's DART MAX™ software and integrated to include a wide range of add-ons as set out for EST4000 (S). The system will include 4K resolution, computer generated imagery (CGI), extensive use of Artificial Intelligence (AI), Arabic language models and an unlimited ability to self-create and save scenarios and training activities. EST4000 (A) offers tailored, game-changing technology to the Middle East and Singapore with incredible AI growth opportunities. To learn more about Cubic products and services, visit About CubicCubic creates and delivers technology solutions in transportation that make people's lives easier by simplifying their daily journeys, and defense capabilities that help promote mission success and safety for those who serve their nation. Led by our talented teams around the world, Cubic is driven to solve global challenges through innovation and service to our customers and partners. Part of Cubic's portfolio of businesses, Cubic Defense provides networked Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance and Reconnaissance (C5ISR) solutions and is a leading provider of live, virtual, constructive and game-based training solutions for both U.S. and Allied Forces. These mission-inspired capabilities enable assured multi-domain access; converged digital intelligence; and superior readiness for defense, intelligence, security and commercial missions. Media Contact: Geri MacDonald Cubic Defense Touchdown PR for Cubic Defense Cubicdefense@ SOURCE: Cubic Defense press release
Business Wire
04-08-2025
- Business Wire
Moody's Wildfire Risk Model Successfully Completes California Department of Insurance Review Process
NEW YORK--(BUSINESS WIRE)--Moody's Corporation (NYSE:MCO) announced today that the Moody's RMS U.S. Wildfire Model v2.0 has successfully completed the review process established by the California Department of Insurance (CDI). This critical milestone will enable insurers to use the forward-looking catastrophe model in their residential rate filings, supporting California's Sustainable Insurance Strategy aimed at stabilizing the state's property insurance market. The Moody's wildfire risk model will allow insurers to leverage the model's advanced, science-driven analytics to assess and price wildfire risk. This enhanced risk assessment is designed to support a more resilient and accessible insurance market – particularly in wildfire-prone areas. 'At Moody's, we are committed to providing markets with transparent, scientifically rigorous tools to decode today's interconnected risks,' said Michael Steel, Head of Insurance Solutions at Moody's. 'Today's milestone marks a significant step forward in addressing the complexities of wildfire risk and promoting greater resilience for insurers, regulators, and homeowners alike.' The Moody's RMS U.S. Wildfire Model v2.0 represents a major advance in capturing the complexities of wildfire behavior, including extreme urban conflagration events. A key feature of the model is its ability to directly account for property-level and community-wide mitigation efforts. By incorporating property-specific data aligned with California regulations, the model will empower insurers to recognize and reward homeowners for risk-reduction efforts, creating tangible incentives that strengthen resilience. Moody's RMS U.S. Wildfire Model v2.0 was reviewed under the CDI's rigorous Pre-Application Required Information Determination procedure, which includes extensive examination of its hazard, vulnerability, and actuarial components. Already in use by leading global insurers, reinsurers, and financial institutions, the model is available on the Moody's RMS Intelligence Risk Platform™ along with Risk Modeler™ and ExposureIQ™ to support a full range of wildfire risk management activities. About Moody's Corporation In a world shaped by increasingly interconnected risks, Moody's (NYSE: MCO) data, insights, and innovative technologies help customers develop a holistic view of their world and unlock opportunities. With a rich history of experience in global markets and a diverse workforce of approximately 16,000 across more than 40 countries, Moody's gives customers the comprehensive perspective needed to act with confidence and thrive. Learn more at 'Safe Harbor' statement under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this document are forward-looking statements and are based on future expectations, plans and prospects for Moody's business and operations that involve a number of risks and uncertainties. Such statements involve estimates, projections, goals, forecasts, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements. Stockholders and investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements and other information in this document are made as of the date hereof, and Moody's undertakes no obligation (nor does it intend) to publicly supplement, update or revise such statements on a going-forward basis, whether as a result of subsequent developments, changed expectations or otherwise, except as required by applicable law or regulation. Factors, risks and uncertainties as well as other risks and uncertainties that could cause Moody's actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements are described in greater detail under 'Risk Factors' in Part I, Item 1A of Moody's annual report on Form 10-K for the year ended December 31, 2024, and in other filings made by the Company from time to time with the SEC or in materials incorporated herein or therein. Stockholders and investors are cautioned that the occurrence of any of these factors, risks and uncertainties may cause the Company's actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements, which could have a material and adverse effect on the Company's business, results of operations and financial condition.
